Insights

Panelists discuss how prescription digital therapeutics (PDTs) can serve as adjunctive treatments to traditional medications for addressing the often-overlooked negative symptoms of schizophrenia, such as social withdrawal and cognitive deficits, by providing personalized, smartphone-based interventions that improve treatment adherence and help patients develop social skills and cognitive rehabilitation in a more accessible format than traditional therapy.

Ryan Haumschild, PharmD, MS, MBA, CPEL; Patricia K. Coyle, MD, and Kavita V. Nair, PhD, FAAN discuss how progression independent of relapse activity (PIRA) represents a critical driver of disability in multiple sclerosis that requires new therapeutic approaches, biomarkers for early identification, and treatment strategies that address both the relapsing inflammatory component and the underlying smoldering neurodegeneration that manifests clinically around midlife.

Catherine M. Broome, MD, discusses how immune thrombocytopenia (ITP) is diagnosed, classified, and managed, including bleeding risk assessment, quality of life impacts, personalized treatment approaches, and future directions for addressing this heterogeneous autoimmune disorder that causes low platelet counts.

Bradley J. Monk, MD, FACS, FACOG; Kathleen Moore, MD, MS, and Floortje J. Backes, MD discuss how comprehensive molecular testing in ovarian cancer has evolved to include BRCA, folate receptor alpha, and emerging biomarkers like HER2 and CCNE1 while addressing challenges in education, reimbursement, and tumor heterogeneity that impact widespread adoption.

Ryan Haumschild, PharmD, MS, MBA, CPEL, and Casey Butrus, PharmD, discuss the challenges related to stakeholder adoption of biosimilars, such as perspectives from pharmacy benefit managers, regional payers, health systems, and private label agreements, and assess strategies to enhance market uptake.

Panelists discuss how emerging Bruton tyrosine kinase (BTK) inhibitors and combination regimens are addressing unmet needs in the treatment of chronic lymphocytic leukemia(CLL) and mantle cell lymphoma (MCL), with a focus on improving outcomes for treatment-naive patients and advancing current therapeutic strategies.

Hadar Lev-Tov, MD, discusses the challenges in patient identification and diagnosis of hidradenitis suppurativa (HS), with a focus on early warning signs. He evaluates the latest American Academy of Dermatology (AAD) guidelines for the treatment of HS and their evolution over time and discusses the multidisciplinary care approach within HS centers and the potential impact of establishing HS Centers of Excellence on patient outcomes.

Robert M. Rifkin, MD, FACP, discusses how real-world studies on teclistamab and talquetamab presented at ASH 2024 align with clinical trial data and reveal key differences, while panelists discuss how clinicians should prioritize patient characteristics and prior treatments when selecting the most appropriate bispecific therapy for relapsed/refractory multiple myeloma.

Panelists discuss how industry-provided patient support services can address the physical, emotional, and practical challenges faced by patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), from diagnosis through treatment and beyond.

A medical expert discusses the key aspects of Lambert-Eaton Myasthenic Syndrome (LEMS) in the context of small cell lung cancer (SCLC), including its differential diagnosis, long-term effects, economic burden, and how a multidisciplinary approach can optimize patient care and reduce health care

Paul Feuerstadt, MD, FACG, AGAF, discusses how antibiotics remain the initial treatment for Clostridioides difficile infections, but due to limited efficiency and recurrence rates, newer therapies including fecal microbiota transplantation (FMT), Rebyota (a purified live biotherapeutic), and Vowst (an oral microbiota therapeutic) have emerged as FDA-approved options that restore gut microbiome diversity and show promising efficiency in preventing recurrent infections, particularly in patients who have failed standard antibiotic therapy.

Reynold A. Panettieri Jr., MD, discusses the role of type 2 inflammation in COPD and asthma, emphasizing its potential to impair lung function.

Susan Perlman, MD, provides a comprehensive overview of Friedreich's ataxia management, encompassing current guidelines, FDA-approved therapies, assessment tools, and prospects for the treatment landscape.

Justin Oldham, MD, MS, provides clinical insights on the evolving treatment landscape in idiopathic pulmonary fibrosis.

Iltefat Hamzavi, MD, provides comprehensive insights on hidradenitis suppurativa (HS), highlighting disease characteristics, treatment practices, and the disease’s profound impact on patients and families.

Ronald Oudiz, MD, FACP, FACC, FCCP, provides clinical insights on the evolving treatment landscape for patients with pulmonary arterial hypertension, focusing onemerging therapies and integrating them into clinical practice.

Robert Gabbay, MD, PhD, discusses type 1 diabetes by addressing the distinct stages of the disease, risk factors, and current and emerging treatments.

Elizabeth Spencer, MD, discusses treatments for eosinophilic esophagitis (EoE), caregiver challenges, therapy struggles, insurance hurdles, and patient advocacy needs.

Expert perspective delves into nature of bronchiectasis and navigates its current treatment landscape across various patient populations.

Mirna Chehade, MD, MPH, describes the symptoms of eosinophilic esophagitis in pediatric patients, and discusses the importance of prompt diagnosis, tailored treatments, and shared decision-making for better patient outcomes.

Elizabeth Yeu, MD, highlights the current landscape of Demodex blepharitis and available treatment options.

Joseph M. Coney MD, FACS, discusses key factors needed to address disparities in care among patients with diabetic macular edema, including the significance of community involvement and the role of provider self-reflection in facilitating fair and unbiased medical care.

Experts discuss novel therapies, unmet needs, and supportive care measures for patients with metastatic non-small cell lung cancer (mNSCLC).

A medical expert discusses current and prospective treatment strategies for RSV.

Eliot Brinton, MD, highlights disease burden and treatment considerations for patients with homozygous familial hypercholesterolemia (HoFH).

David Lieberman, MD, PhD, provides an overview of Rett Syndrome, explores the patient perspective of Rett Syndrome, and discusses methods clinicians and payers use to evaluate treatment successes.

Two experts discuss the burden of disease, the treatment landscape, and the urgency to treat lupus nephritis.